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42 molecules which were sold in each country for the period. The countries were 
organised into the WHO regions. In total, around 1,000,000 unique national, product 
brands were accessed for the analysis. Results: Pharmaceutical price indices vary 
substantially between regions. The Asian regions recorded the lowest prices. The 
indices were as follows: South-East Asian Region D 0.21; South-East Asian Region 
B 0.31; European Region B 0.37 Western Pacific Region A; 0.44 European Region A 
0.45; African Region E 0.46; European Region C 0.49; Western Pacific Region B 0.51; 
Eastern Mediterranean Region D; 0.54; Region of the Americas D 0.87; Region of the 
Americas B 0.90; Eastern Mediterranean Region B 1.11. ConClusions: This is the 
largest exercise ever undertaken in comparing international pharmaceutical prices. 
It also employs a more robust method than previous studies. The analysis shows 
Asian region pharmaceutical prices are the lowest in the world.
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objeCtives: Review existing literature to understand the prevalent external price 
referencing (EPR) systems and to audit for directionality of the current mechanisms 
against the components defined in WHO/HAI (World Health Organization/Health 
Action International) project on EPR. Methods: English publications between 
October 2000 and March 2013 investigating EPR systems were identified through 
EBM Reviews – Cochrane Database of Systematic Reviews, NHS Economic Evaluation 
Database; Embase; and MEDLINE searches. Publications on EPR systems were ana-
lyzed in three relevant groups. Qualitative analysis was done to audit the direction-
ality. Results: 101 out of 598 articles were found to be relevant and were placed and 
allocated into three relevant focus groups - 43 general, 44 individual country, and 14 
disease specific reference pricing articles. Regional distribution of publications was 
as follows: 49 RE (Region Europe), 12 Americas, and 15 Asia-Africa-Oceania. Number 
of publications over years was ranging from 3 to 10 with a significant peak in 2011 
at 21.52 articles were found to have directionality against the components defined 
in WHO/HAI project, and the use of several approaches for setting the price was 
commonly discussed. Use of EPR was discussed for both patented and generic drugs. 
Publications showed directionality towards use of several approaches for EPR and 
were directing the use of EPR for both patented and generic drugs. With regards to 
type of price level used, ex-manufacturer price was the dominant option. The for-
mula to derive the target price was directing towards average price. ConClusions: 
There is a growing trend towards increase in number of publications on EPR with 
lead from RE. A number of discussions around the components raised on WHO/HAI 
Project indicate that it is a useful tool to lay out options for ERP. Growing number 
of publications will provide more robust evidence for commonly used options of 
each component.
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objeCtives: In 2003, China introduced a heavily subsidized voluntary health insur-
ance program, the New Rural Cooperative Medical Scheme (NRCMS). This paper 
evaluates the effectiveness of the NRCMS by assessing its impact on health care 
utilization and out-of-pocket health expenditure. Methods: We employ propensity 
score matching (PSM) with single difference and double difference based on data 
from China Health and Nutrition Survey (CHNS) from 1991 to 2009. To check the 
robustness of our results, we also use a bounding approach to test how strongly an 
invariant unobserved variable influences the selection process. For the out-of-pocket 
payments (OOP), a two-part model is used to correct for the large number of zero 
values and the skewness of the data. Results: We find no evidence of an increase 
in the utilization of formal medical care and preventive services. There is a large, 
positive effect on the utilization of village clinics, and large, negative effects in 
town hospitals, county hospitals and city hospitals. For the two-part model of out-
of-pocket (OOP) payments, we find a small, positive impact on the probability of 
positive OOP payments and a small, negative impact on the actual level of OOP pay-
ments. All the effects on the incidence of catastrophic medical payments based on 
different thresholds are insignificant. ConClusions: The results indicate that the 
NRCMS did not increase the overall utilization but directs people from high-level to 
low-level medical facilities. The substitution effect among different levels of facili-
ties may be due to more generous reimbursement in low-level facilities. In addi-
tion, there is no reduction on the out-of-pocket medical payments or the incidence 
of catastrophic health payments. Therefore, the impact of NRCMS on increasing 
utilization and reducing financial risk is found to be limited. The lack of effective-
ness may be attributed to a relatively low premium and shallow benefit coverage.
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objeCtives: To examine the time between regulatory approval and launch/pricing 
and reimbursement (P&R) approval in the EU5 and US. Methods: New molecular 
entities, formulations and combinations approved by the EMA between January 
2009 and December 2013 were included in the analysis. FDA approval dates were 
retrieved and launch dates were gathered as follows: USA: Date wholesale acquisi-
tion cost was effective; UK/Germany: Product availability/introduction; France: P&R 
decision (Agrément collectivités/date published in Journal Officiel); Italy: First P&R 
Decree publication on Official Gazette; Spain: Date of commercialization; and Time 
comparison for general medicines vs. orphan and oncology indications was made 
including shifts over time. Results: Time from approval to launch in the US aver-
plantation purpose. Almost all Category 2A new drugs fulfilled the unmet medical 
needs for infection control, tocolytic therapy in preterm labor, or new mechanism for 
cardiovascular disease. ConClusions: Category 2B new drugs with less financial 
impact to NHI system seem easier to reach listing and reimbursement goal in the 
2-stage assessments. Reasonable budget impact and cost-effectiveness analysis are 
as important as robust comparative effectiveness data for PBRS appraisals. There is 
a need for long-term observation and further analysis.
PHP57
an analysis of tHe Key value drivers for Hta assessments in taiwan
Park S.1, Jiang Y.1, Sun D.1, Beckerman R.2
1CBPartners, New York City, NY, USA, 2CBPartners, New York, NY, USA
objeCtives: The purpose of this study was to identify the main value drivers behind 
the innovation category designations (1, 2A, 2B) assigned during the Taiwanese 
reimbursement process. Methods: All products assessed for reimbursement 
from January 2012 to March 2014 by the National Health Insurance Administration 
(NHIA) were considered in this analysis. The details of the assessments have been 
extracted from the NHIA meeting minutes and Center for Drug Evaluation (CDE) 
reports. Results: Category 1 designations are given to drugs that show “substantial 
clinical improvement”, Category 2A designations to drugs that exhibit “moderate 
improvement”, and Category 2B designations to drugs that provide similar clinical 
value to comparators. Since 2012,94 of 113 products received positive decisions 
from the NHIA. 19 received Category 2A (26%), 51 received Category 2B (71%), while 
2 received Category 1 (3%). Most Category 2B drugs were considered as alternative 
therapeutic options with similar efficacy (94%) to an existing product; others were 
considered to provide better clinical value but a larger budget impact or higher 
price (6%). Most Category 2A drugs were considered to provide additional efficacy, 
safety, or convenience over the comparator (53%). Of the 2 Category 1 products, 
plerixafor was rewarded for its curative potential in hematologic malignancies, as 
well as its potential reduction of hospitalisation costs; azacitidine was rewarded 
for being a first-in-class therapy for Myelodysplastic Syndrome. 22 of 94 products 
did not receive any category, as they were indication expansions. 17 of 113 assessed 
products received negative decisions due to their significant budget impact (59%) 
or lack of clinical benefit (41%). 2 out of 113 decisions are pending. ConClusions: 
Both clinical and economic considerations heavily drive the assessment outcomes 
in Taiwan. In order to achieve a positive assessment outcome in Taiwan, a product 
needs to provide a combination of favourable clinical and economic data.
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objeCtives: Pharmaceuticals can be marketed when regulatory approval has been 
obtained. However other barriers may need to be cleared before patients can gain 
access to subsidised medicines. In the Asia-Pacific region these subsidised systems 
are often government programmes and range from national tax funded schemes 
(Australian Pharmaceutical Benefits Schedule) through to coverage of a specific 
population (Thailand Social Security Scheme for office workers). Navigating these 
systems can be as simple as submitting a pricing application or as complex as a 
full scale societal health technology assessments. The aim of this study is to com-
pare the processes and timings between regulatory approval and subsidised access 
to medicines across the Asia-Pacific region. Methods: Reimbursement guide-
lines from seven different jurisdictions in the Asia-Pacific region were reviewed. 
Differences in processes and time from regulatory approval to subsidised access 
were captured between Australia, China, Japan, Korea, New Zealand, Taiwan and 
Thailand. Results: Only Australia and Thailand allows evaluation of reimburse-
ment in parallel with regulatory evaluation. Parallel processing has been discussed 
in Korea and Taiwan but has not been implemented. The time between regulatory 
approval and subsidised access differs across jurisdictions. In general additional 
processes such as health economic evaluation, pricing negotiation, budget approval 
and administration prolong time to subsidised access well beyond 6 months post 
regulatory approval. Japan is unique as a reimbursement price should be published 
within 60 days after regulatory approval. ConClusions: While most jurisdictions 
in the Asia-Pacific region differ in terms of regulatory and access approval pro-
cesses all but one of the jurisdictions included in this study require a regulatory 
approval letter before reimbursement can be sought. Parallel processing can shorten 
time for patients to access new medicines however other factors such as health 
economic evaluation, pricing negotiation, budget approval and administration are 
also important.
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objeCtives: The study aimed to determine the differences between Asian and 
Global Pharmaceutical prices Methods: The indices were developed using the 
Fisher Elteto, Koves, Szulc (EKS) method. The EKS method is widely used by the 
Organisation for Economic Co-operation and Development (OECD) but has not 
yet been applied to pharmaceutical prices. IMS MIDAS data was used to estimate 
prices and sales volumes. In order to construct the indices, the products needed 
to be defined as like. The definition of like in this study was based on molecules 
which are deemed to deliver equivalent health outcomes. The price indices were 
developed for countries in World Health Organisation (WHO) regions. The analysis 
compares prices across 56 countries over the period from 2005 to 2011 and included 
